Turbulence ahead for the life sciences industry – which steps you have to take NOW
The separation of Veeva and Salesforce in September 2025 poses important questions: How will the market leaders in the pharmaceutical industry adapt? What challenges and opportunities will this present? What does this mean for the future of CRM systems in one of the most heavily regulated industries?
Migration is inevitable. Where to migrate must be carefully considered. What are the alternatives?
From Veeva CRM to the new Vault CRM or from IQVIA OCE to Salesforce Life Sciences Cloud? Or directly to other CRM providers? We recently had an impressive onboarding with Ysura. Alternatively, there are countless other solutions like Exeevo, Pharmakon, Vtiger or even Hubspot?
Effective CRM systems are crucial for managing customer relationships, marketing strategies and compliance, especially in the life sciences sector.
Changing CRMs can have a significant impact on the efficiency and productivity of a company in different business areas. A smooth transition can only succeed with timely planning and comprehensive expertise.
Maintaining business continuity is the cornerstone for all decisions.
Planning errors quickly become expensive if, for example, the field force can no longer access essential software or if content cannot be distributed because it is not compatible or trackable.
Our recommendation is to familiarize yourself with the options you have and pitfalls you might face as quickly as possible and to ask the right questions early on.
Our whitepaper “Quo vadis Pharma CRM” sheds light on the impact of these developments and provides an outlook on the upcoming changes.
Our view is certainly not the only perspective.
We are always grateful for feedback from other perspectives – the more diverse the discourse, the better the results. Follow the white paper discussion on LinkedIn and share your thoughts in the comments.